Drug intelligence / Profile preview

OvamiR

Development stage: Preclinical
Lead developer: AptamiR Therapeutics
Modality: RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Intraperitoneal, Subcutaneous

Overview

OvamiR is a microRNA oligonucleotide therapeutic (ONT) being developed by AptamiR Therapeutics for the treatment of epithelial ovarian cancer, specifically high-grade serous ovarian cancer (HGSOC). Currently in the preclinical candidate selection phase, the program aims to utilize microRNA-based technology to target the underlying biology of HGSOC. While the specific molecular targets and mechanism of action have not been publicly detailed, the therapeutic is designed to modulate gene expression pathways involved in ovarian malignancy.

Other names: OvamiR

Beyond the preview

Go deeper on OvamiR.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OvamiR.

Explore the full profile